AbCellera Biologics Inc. ABCL · NASDAQ
$11.80 -6.94% (-$0.88)
Summary
25 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Revenue fell by 46% a year over the last 3 years.
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Analysts expect revenue to fall by 65% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 20% a year over 5 years. Over the last 3 years it fell by 46% a year. For the next fiscal year analysts expect revenue to fall by 65%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $164.7M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $15.4 is 31% above today's price. 92% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License 62%
- Research Fees 36%
- Milestone Payments 1.3%
By region
- CANADA 85%
- UNITED STATES 15%
License brings in 62% of revenue.
Segments in detail